Faculty are encouraged to apply for the T1 Translational Catalyst Award, which is designed to help drive promising, early-stage research through the lengthy and complex process of bringing products and procedures to patients.

A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.